Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants

Conavi Medical Corp. (TSXV: CNVI) (“ Conavi ” or the “ Company ”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The offering is of common shares of the Company (“ Common Shares ”) and/or pre-funded common share purchase warrants of the Company (“ Pre-Funded Warrants ” and, together with the Common Shares, the “ Securities ”) in lieu of Common Shares (the “ Offering ”). The Offering is being conducted on a commercially reasonable efforts agency basis for the issuance of a minimum of 50,000,000 Securities and a maximum of 75,000,000 Securities at a price of $0.20 per Common Share or $0.19999 per Pre-Funded Warrant, for gross proceeds of between $10,000,000 and $15,000,000. Each Pre-Funded Warrant issued in lieu of a Common Share at the election of any purchaser entitles the holder thereof to acquire one Common Share at an exercise price of $0.00001 per Common Share. The Pre-Funded Warrants will not expire and may be exercised on a “net” or “cashless” basis. The Company intends to use the net proceeds from the Offering to complete a limited market release in the United States. The Company also intends to use the net proceeds for working capital and other general corporate purposes. The Offering is expected to be completed pursuant to the terms and conditions of an agency agreement entered into between the Company and Bloom Burton Securities Inc. (“ Bloom Burton ”), on behalf of a syndicate of agents (collectively, the “ Agents ”). The Company is expecting to file today, on July 29, 2026, a final short form prospectus (the “ Final Prospectus ”) with the securities regulatory authorities in the provinces of Alberta, British Columbia, and Ontario. There will not be any sale of Securities until a receipt for the Final Prospectus has been issued. The Offering may be completed in one or more tranches and is expected to close initially on or about August 5, 2026, or such other date as may be mutually agreed to by the Company and the Agents (the “ Closing Date ”). The Offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange (“ TSXV ”). The Company will pay to the Agents a cash fee equal to 6.5% of the gross proceeds raised under the Offering, and grant the Agents compensation options equal to 6.5% of the aggregate number of Securities issued under the Offering (the “ Compensation Options ”), provided however the Agents will receive a reduced cash commission of 3.25% and no Compensation Options in respect of Securities sold to certain purchasers on a president’s list to be agreed to between the Company and the Agents. Each Compensation Option shall entitle the holder to buy one Common Share at the same price per Common Share as under the Offering. The Compensation Options shall be exercisable until that date which is 24 months following the Closing Date. In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.